Content about Organ failure

July 31, 2012
MinuteClinic, American Heart Association collaborate for hypertension management

CVS Caremark’s MinuteClinic has teamed up with the American Heart Association in a nationwide effort to improve the identification, treatment and management of high blood pressure.

WOONSOCKET, R.I. — CVS Caremark’s MinuteClinic has teamed up with the American Heart Association in a nationwide effort to improve the identification, treatment and management of high blood pressure.

According to the American Heart Association, 1-out-of-3 American adults has high blood pressure or hypertension. Uncontrolled high blood pressure can lead to stroke, heart attack, heart failure and kidney failure.

June 7, 2012
Perrigo wins approval for renal failure drug

The Food and Drug Administration has approved a drug for kidney disease made by Perrigo.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug for kidney disease made by Perrigo.

Perrigo announced the approval of calcium acetate capsules, a generic version of Nabi Biopharmaceuticals' Phoslo Gelcaps. The drug is used to treat end-stage renal failure.

Perrigo settled a patent infringement lawsuit concerning the drug last year, though terms of the settlement were not disclosed. Annual sales of the branded version of the drug and generic versions were $95 million, according to Wolters Kluwer Health.

March 28, 2012
FDA approves Omontys for kidney disease-related anemia

The Food and Drug Administration has approved a new treatment for anemia in patients with chronic kidney disease.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for anemia in patients with chronic kidney disease.

The FDA announced the approval of Affymax's Omontys (peginesatide), a drug belonging to the class known as erythropoiesis-stimulating agents, designed to aid the formation of red blood cells.

February 25, 2011
Type 1 diabetics continue to be at risk for kidney disease

Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.

BOSTON — Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.

December 1, 2010
Keryx: Zerenex reduces phosphate levels in patients on kidney dialysis

Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

NEW YORK — Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

In a phase-3 trial, Zerenex (ferric citrate) significantly reduced phosphate levels in patients with end-stage kidney disease on dialysis.

September 22, 2010
Abbott, Reata ink deal for chronic kidney disease treatment

Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic...

ABBOTT PARK, Ill. Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic kidney disease.

 

The two companies said Thursday that they would develop and commercialize bardoxolone methyl, currently in mid-stage clinical trials.

 

 

February 1, 2010
'Silent strokes' linked to kidney failure in diabetics

Tiny areas of brain damage caused by injury to small blood vessels can signal an...